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arriers of carbapenem-resistant Enterobacteriaceae (CRE)
nd dedicated stafﬁng, and appointed a professional task
orce charged with containing spread of the epidemic strain.
he task force paid site visits at acute care hospitals, eval-
ated infection control policies and laboratory methods,
upervised adherence to the guidelines via daily census
eports on carriers and their conditions of isolation, provided
egular feedback on performance to hospital directors, and
ntervened additionally when necessary. During 2008, the
ntervention was extended to long-term care facilities, and
n June 2008 national guidelines for active surveillance were
ssued. The primary outcome measure was the incidence
f clinically diagnosed nosocomial CRE cases in acute care
ospitals.
Results: By March 2007, over 1200 patients were affected
n acute care hospitals. Prior to the intervention, the
onthly incidence of noscomial CRE climbed steadily, peak-
ng at over 180 cases. Crude 30-day mortality was > 30%.
ith the intervention, the continuous rise in incidence of
RE acquisition was halted, and at the end of the 14-month
nitial intervention period the number of new monthly cases
as 46. Following the introduction of active surveillance
uidelines, monthly incidence fell further, reaching a low
f 24 as of October 2009. A direct correlation was observed
etween compliance with isolation guidelines and success in
ontainment of in-hospital CRE transmission.
Conclusions: A centrally-coordinated public health inter-
ention has succeeded in containing a nationwide outbreak
f CRE in Israeli hospitals after local measures failed.
he intervention demonstrates the importance of strategic
lanning and national oversight in combating antimicrobial
esistance.
oi:10.1016/j.ijid.2010.02.1884
1.004
reatment Options for Carbapenenam Resistant Infections
. Daikos
University of Athens, Athens, Greece
Carbapenemase producing Gram-negative bacteria
CPGN) become increasingly prevalent and cause serious
nfections resulting in high fatality. These organisms are
esistant, not only to almost all available !-lactam antibi-
tics but also to other classes of agents, leaving tigecycline
nd colistin as the only therapeutic options. None of
hese agents, however, is ideal; tigecycline produces low
lood levels and colistin has questionable performance in
erious infections owing to poor pharmacokinetics. More
orryingly, resistance to both of these compounds has been
eveloped. The newer !-lactamase inhibitors, NXL 104 and
AL 30376, show promises for infections caused by CPGN. A
roportion of carbapenemase-producing Enterobacteriacae
as MICs of carbapenems within the susceptible range
aising the critical question of whether carbapenems might
e effective in the treatment of infections caused by such
rganisms.Anecdotal reports claim microbiological and clinical
esponse in patients infected with MBLpositive carbapenem-
usceptible organisms after treatment with a carbapenem.
n a prospective study of 67 patients with bloodstream infec-
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ions caused by VIM-producing K. pneumoniae, the lowest
ortality was observed in the group of patients who had
eceived combination therapy with two active drugs, one
f which was a carbapenem and the other either colistin or
n active aminoglycoside, whereas therapy with one active
rug resulted in a mortality similar to that observed in
atients who had received therapy with no active drug.
ased on this experience, it remains doubtful whether
onotherapy with a carbapenem would be effective in the
reatment of such infections. On the other hand, carbapen-
ms in combination with another active agent may provide
ome therapeutic beneﬁt against MBL-positive carbapenem-
usceptible Enterobacteriaceae. In this respect, the issue of
ither reporting such isolates as fully resistant to carbapen-
ms or consider the respective MICs at face value should
emain open. In conclusion, information about how to treat
nfections caused by CPGN is surprisingly scarce.
oi:10.1016/j.ijid.2010.02.1885
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2.001
alaria Eradication
.V. Plowe
University of Maryland School of Medicine, Baltimore21201,
D, USA
A global campaign to eradicate malaria in the middle
f the last century relied chieﬂy on two powerful tools,
nsecticide spraying of mosquitoes to interrupt transmission
nd chloroquine treatment to reduce the human reservoir
f infection. While this effort, led by the World Health
rganization, did succeed in eliminating malaria from some
reas on the edges of the malaria map, it was aban-
oned as a failure after little more than a decade. The
mergence of insecticideresistant Anopheles mosquitoes
nd drug-resistant Plasmodium falciparum parasites, failure
o understand and adapt to local differences in mosquito
cology and malaria epidemiology, and donor fatigue, all
ontributed to the demise of the campaign, which never
ncluded Africa, the region with by far the greatest malaria
urden, then and now. In the ensuing decades, the focus
hifted from eradication to control, and worldwide malaria
eaths increased in the face of chloroquine resistant falci-
arum malaria and weak health care systems.
The development and deployment of two new tools,
ong-lasting insecticide-treated nets and artemisinin-based
ombination drug treatments, have led to dramatic reduc-
ions in malaria in several countries, including some
n Africa. Malaria has even been completely eliminated
ecently from some endemic areas with low levels of trans-
ission and relatively good health infrastructure. These
uccess stories have generated such optimism that Bill
nd Melinda Gates and other donors and, following their
ead, malariologists, are talking again about eradication. To
chieve a better outcome than the ﬁrst campaign, malaria
radicators in the 21st century will need to learn and apply
essons from both past and recent failures and successes.
f a renewed malaria eradication effort is started with the
ools in hand now, it will be essential to keep the pipeline
trac
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members of babies in the NICU will further reduce the like-
lihood of introducing community-associated pathogens into
the NICU.14th International Congress on Infectious Diseases (ICID) Abs
ﬂowing with improved insecticides and drugs to replace
those that succumb to resistance, as well as to develop new
tools, including safe and effective drugs and vaccines that
block malaria transmission. Prospects for malaria eradica-
tion may be jeopardized by the apparent recent emergence
of artemisinin-resistant falciparum malaria in Southeast
Asia.
doi:10.1016/j.ijid.2010.02.1886
A rational approach for the treatment and preven-
tion of neonatal sepsis (Invited Presentation)
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Global Burden of Neonatal Sepsis
E.K. Mulholland1,∗, E. Fenn2, A. Zaidi 3
1 London School of Hygiene and Tropical Medicine, London,
United Kingdom
2 Menzies School of Health Research, Darwin, Australia
3 Aga Khan University, Karachi, Pakistan
As infant and child mortality declines in many developing
countries, neonatal mortality becomes the dominant com-
ponent of all child mortality, now constituting about 40% of
child deaths. As attention is focused on this problem, it is
becoming clear that, in the high mortality countries, neona-
tal mortality rates are being systematically underestimated,
especially in the poorest, most marginalized communities.
Data on the causes of neonatal deaths in the community are
seriously inadequate, as deaths occur outside the health ser-
vice, and post mortem questionnaires are very difﬁcult to
interpret in this age group. Studies that examined the inci-
dence and mortality due to neonatal sepsis were reviewed.
We sought to determine the relationship between the neona-
tal mortality rate and the proportion of neonatal deaths
due to infection. From a review of 32 community based
studies published since 1990, between 8% and 80% of all
neonatal deaths in different regions of the developing world
are reported as being due to infectious causes. Similar wide
variability is seen in the incidence of clinical neonatal sep-
sis, with reported rates varying from 49 per 1000 live births
in rural Guatemala to as high as 170 per 1000 live birthsin
rural India. The ﬁeld of neonatal mortality, and speciﬁcally
neonatal sepsis, in developing countries is obscured by a
lack of credible data. Neonatal sepsis rates are confounded
by lack of clear clinical deﬁnitions, and even neonatal mor-
tality rates are very unclear. Without any clear means of
determining the cause of community neonatal deaths, the
contribution of sepsis to overall mortality is equally unclear.
The need for new and innovative research in this ﬁeld is
overwhelming.
doi:10.1016/j.ijid.2010.02.1887
dts e181
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ational Use of Antibiotics in the Critically Ill Neonate and
he Premature Infant
. Odio
Hospital Nacional de Ninos and School of Medical Sciences,
an Jose, Costa Rica
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3.004
trategies to Limit Infections in the Neonate and to
educe Infection-related Mortality
. Sanchez
University of Texas Southwestern Medical Center, Dallas,
X, USA
Health-care associated infections remain a major prob-
em in the neonatal intensive care unit (NICU), resulting
n signiﬁcant morbidity and mortality. Speciﬁcally, blood-
tream infections have been associated with adverse
eurodevelopmental outcomes among preterm infants with
irth weight <1000 grams. In addition, these infections are
ssociated with prolonged duration of hospitalization among
urvivors and increased cost of neonatal health care. It is
lear that preventive strategies are urgently needed.
Many bloodstream infections in the NICU are associated
ith the use of central venous catheters, and implemen-
ation of evidence-based measures as well as bundles
as reduced their occurrence. Nevertheless, much work
emains. Candidal infections have become more prevalent
n the NICU, and ﬂuconazole prophylaxis is being recom-
ended and used to prevent candidiasis among infants with
irth weight <1000 grams. Although ﬂuconazole prophylaxis
as reduced invasive candidal infections, the underlying risk
actors that result in Candida becoming a more common
athogen remain, namely the overuse of antibiotics espe-
ially the third generation cephalosporins. In addition, the
se of H2 blocker also has contributed to Candidal coloniza-
ion and late onset sepsis. Recent results of randomized
linical trials have shown beneﬁcial effects of probiotics
or prevention of necrotizing enterocolitis and lactoferrin
or prevention of late onset sepsis. Finally, the need to
accinate not only our preemies but also staff and familyoi:10.1016/j.ijid.2010.02.1889
